• Je něco špatně v tomto záznamu ?

Short- and long-term adverse events in patients on temporary circulatory support before durable ventricular assist device: An IMACS registry analysis

VK. Ton, R. Xie, JA. Hernandez-Montfort, B. Meyns, T. Nakatani, M. Yanase, S. Shaw, S. Pettit, I. Netuka, J. Kirklin, DJ. Goldstein, J. Cowger

. 2020 ; 39 (4) : 342-352. [pub] 20200121

Jazyk angličtina Země Spojené státy americké

Typ dokumentu časopisecké články, multicentrická studie

Perzistentní odkaz   https://www.medvik.cz/link/bmc21020658

BACKGROUND: Patients with cardiogenic shock (CS) needing temporary circulatory support (TCS) have poor survival rates after implantation of durable ventricular assist device (dVAD). We aimed to characterize post-dVAD adverse event burden and survival rates in patients requiring pre-operative TCS. METHOD: We analyzed 13,511 adults (Interagency Registry for Mechanically Assisted Circulatory Support [INTERMACS] Profiles 1-3) with continuous-flow dVADs in International Society for Heart and Lung Transplantation Registry for Mechanically Assisted Circulatory Support (2013-2017) according to the need for pre-operative TCS (n = 5,632) vs no TCS (n = 7,879). Of these, 726 (5.4%) had biventricular assist devices (BiVAD). Furthermore, we compared prevalent rates (events/100 patient-months) of bleeding, device-related infection, hemorrhagic and ischemic cerebrovascular accidents (hemorrhagic cerebral vascular accident [hCVA], and ischemic cerebral vascular accident [iCVA]) in early (<3 months) and late (≥3 months) post-operative periods. RESULTS: TCS included extracorporeal membrane oxygenation (ECMO) (n = 1,138), intra-aortic balloon pump (IABP) (n = 3,901), and other TCS (n = 593). Within 3 post-operative months, there were more major bleeding and cerebrovascular accidents (CVAs) in patients with pre-operative ECMO (events/100 patient-months rates: bleeding = 19, hCVA = 1.6, iCVA = 2.8) or IABP (bleeding = 17.3, hCVA = 1.5, iCVA = 1.5) vs no TCS (bleeding = 13.2, hCVA = 1.1, iCVA = 1.2, all p < 0.05). After 3 months, adverse events were lower and similar in all groups. Patients with ECMO had the worst short- and long-term survival rates. Patients with BiVAD had the worst survival rate regardless of need for pre-operative TCS. CVA and multiorgan failures were the common causes of death for patients with TCS and patients without TCS. CONCLUSIONS: Patients requiring TCS before dVAD had a sicker phenotype and higher rates of early post-operative adverse events than patients without TCS. ECMO was associated with very high early ischemic stroke, bleeding, and mortality. The extreme CS phenotype needing ECMO warrants a higher-level profile status, such as INTERMACS "0."

Citace poskytuje Crossref.org

000      
00000naa a2200000 a 4500
001      
bmc21020658
003      
CZ-PrNML
005      
20210830102256.0
007      
ta
008      
210728s2020 xxu f 000 0|eng||
009      
AR
024    7_
$a 10.1016/j.healun.2019.12.011 $2 doi
035    __
$a (PubMed)32029401
040    __
$a ABA008 $b cze $d ABA008 $e AACR2
041    0_
$a eng
044    __
$a xxu
100    1_
$a Ton, Van-Khue $u Division of Cardiology, Massachusetts General Hospital, Boston, Massachusetts. Electronic address: kton@partners.org
245    10
$a Short- and long-term adverse events in patients on temporary circulatory support before durable ventricular assist device: An IMACS registry analysis / $c VK. Ton, R. Xie, JA. Hernandez-Montfort, B. Meyns, T. Nakatani, M. Yanase, S. Shaw, S. Pettit, I. Netuka, J. Kirklin, DJ. Goldstein, J. Cowger
520    9_
$a BACKGROUND: Patients with cardiogenic shock (CS) needing temporary circulatory support (TCS) have poor survival rates after implantation of durable ventricular assist device (dVAD). We aimed to characterize post-dVAD adverse event burden and survival rates in patients requiring pre-operative TCS. METHOD: We analyzed 13,511 adults (Interagency Registry for Mechanically Assisted Circulatory Support [INTERMACS] Profiles 1-3) with continuous-flow dVADs in International Society for Heart and Lung Transplantation Registry for Mechanically Assisted Circulatory Support (2013-2017) according to the need for pre-operative TCS (n = 5,632) vs no TCS (n = 7,879). Of these, 726 (5.4%) had biventricular assist devices (BiVAD). Furthermore, we compared prevalent rates (events/100 patient-months) of bleeding, device-related infection, hemorrhagic and ischemic cerebrovascular accidents (hemorrhagic cerebral vascular accident [hCVA], and ischemic cerebral vascular accident [iCVA]) in early (<3 months) and late (≥3 months) post-operative periods. RESULTS: TCS included extracorporeal membrane oxygenation (ECMO) (n = 1,138), intra-aortic balloon pump (IABP) (n = 3,901), and other TCS (n = 593). Within 3 post-operative months, there were more major bleeding and cerebrovascular accidents (CVAs) in patients with pre-operative ECMO (events/100 patient-months rates: bleeding = 19, hCVA = 1.6, iCVA = 2.8) or IABP (bleeding = 17.3, hCVA = 1.5, iCVA = 1.5) vs no TCS (bleeding = 13.2, hCVA = 1.1, iCVA = 1.2, all p < 0.05). After 3 months, adverse events were lower and similar in all groups. Patients with ECMO had the worst short- and long-term survival rates. Patients with BiVAD had the worst survival rate regardless of need for pre-operative TCS. CVA and multiorgan failures were the common causes of death for patients with TCS and patients without TCS. CONCLUSIONS: Patients requiring TCS before dVAD had a sicker phenotype and higher rates of early post-operative adverse events than patients without TCS. ECMO was associated with very high early ischemic stroke, bleeding, and mortality. The extreme CS phenotype needing ECMO warrants a higher-level profile status, such as INTERMACS "0."
650    _2
$a senioři $7 D000368
650    _2
$a mimotělní membránová oxygenace $x škodlivé účinky $7 D015199
650    _2
$a ženské pohlaví $7 D005260
650    _2
$a celosvětové zdraví $7 D014943
650    _2
$a srdeční selhání $x mortalita $x terapie $7 D006333
650    12
$a transplantace srdce $7 D016027
650    _2
$a podpůrné srdeční systémy $x škodlivé účinky $7 D006353
650    _2
$a lidé $7 D006801
650    _2
$a intraaortální balónková pumpa $x škodlivé účinky $7 D007423
650    _2
$a mužské pohlaví $7 D008297
650    _2
$a lidé středního věku $7 D008875
650    12
$a registrace $7 D012042
650    _2
$a míra přežití $x trendy $7 D015996
655    _2
$a časopisecké články $7 D016428
655    _2
$a multicentrická studie $7 D016448
700    1_
$a Xie, Rongbing $u The University of Alabama at Birmingham, Birmingham, Alabama
700    1_
$a Hernandez-Montfort, Jaime A $u Cleveland Clinic Florida, Weston, Florida
700    1_
$a Meyns, Bart $u Gasthuisberg University Hospital, Leuven, Kingdom of Belgium
700    1_
$a Nakatani, Takeshi $u National Cardiovascular Center, Osaka, Japan
700    1_
$a Yanase, Masanobu $u National Cerebral and Cardiovascular Center, Osaka, Japan
700    1_
$a Shaw, Steve $u Wythenshawe Hospital, Manchester, United Kingdom
700    1_
$a Pettit, Stephen $u Royal Papworth Hospital, Cambridge, United Kingdom
700    1_
$a Netuka, Ivan $u IKEM - Institute for Clinical and Experimental Medicine, Prague, Česko
700    1_
$a Kirklin, James $u The University of Alabama at Birmingham, Birmingham, Alabama
700    1_
$a Goldstein, Daniel J $u Montefiore Medical Center, New York, New York
700    1_
$a Cowger, Jennifer $u Henry Ford Health System, Detroit, Michigan
773    0_
$w MED00002704 $t The Journal of heart and lung transplantation : the official publication of the International Society for Heart Transplantation $x 1557-3117 $g Roč. 39, č. 4 (2020), s. 342-352
856    41
$u https://pubmed.ncbi.nlm.nih.gov/32029401 $y Pubmed
910    __
$a ABA008 $b sig $c sign $y p $z 0
990    __
$a 20210728 $b ABA008
991    __
$a 20210830102256 $b ABA008
999    __
$a ok $b bmc $g 1691268 $s 1141104
BAS    __
$a 3
BAS    __
$a PreBMC
BMC    __
$a 2020 $b 39 $c 4 $d 342-352 $e 20200121 $i 1557-3117 $m The Journal of heart and lung transplantation $n J Heart Lung Transplant $x MED00002704
LZP    __
$a Pubmed-20210728

Najít záznam

Citační ukazatele

Možnosti archivace